#China #Kelun-Biotech #Rotterdam #Harbour BioMed #HBM7575

Harbour BioMed and Kelun-Biotech: A New Hope for Atopic Dermatitis

In a significant advancement for patients suffering from atopic dermatitis, Harbour BioMed and Kelun-Biotech have jointly announced that their Investigational New Drug (IND) application for HBM7575/SKB575 has been approved by the National Medical Products Administration (NMPA) in China. This innovative treatment, a long-acting bispecific antibody that targets thymic stromal lymphopoietin (TSLP) and an undisclosed target, aims to address the challenges faced by those battling this chronic inflammatory skin condition.

The Burden of Atopic Dermatitis

Atopic dermatitis is not only a prevalent skin condition affecting approximately 20% of children and up to 10% of adults globally, but also a source of significant emotional and physical discomfort. Patients frequently encounter severe itching, redness, and skin irritation, which can disrupt daily activities and quality of life. Current therapies, including topical treatments and biologics, often provide only temporary relief and fail to control the disease, especially in more severe cases. As such, there is a pressing demand for new, effective therapeutic options that can offer more substantial and lasting relief.

The Innovation of HBM7575/SKB575

Mechanism of Action

HBM7575/SKB575 represents a novel approach to treating atopic dermatitis through its dual action mechanism. It works by blocking TSLP, a key factor in type 2 inflammation, while its second undisclosed target enhances its efficacy by addressing resistance issues common with single-target therapies. The design of this bispecific antibody not only aims to inhibit TSLP-mediated signaling but also generates a synergistic effect that could prove beneficial in managing the condition.

Long-Acting Profile

The unique formulation of HBM7575/SKB575 is engineered for an extended half-life, which allows for fewer doses required over time. Anticipated clinical data suggests that a dosing schedule may exceed three months, which could be transformative for patients used to frequent drug administration. This prolonged efficacy aligns perfectly with the goal of improving patient adherence to treatment regimens.

Statements from Leadership

Dr. Jingsong Wang, the Founder, and CEO of Harbour BioMed, expressed optimism about the IND approval, stating, "This marks a pivotal step forward in addressing the important unmet needs in treating autoimmune diseases like atopic dermatitis. We believe HBM7575/SKB575 could become a best-in-class therapy." Meanwhile, Dr. Michael Ge, CEO of Kelun-Biotech, highlighted the milestone this approval represents in their strategic expansion to develop new treatment avenues for autoimmune diseases, emphasizing the potential to provide patients with an improved treatment experience.

Collaboration for Success

The partnership between Harbour BioMed and Kelun-Biotech is defined by a collaborative approach where Kelun leads the global development and commercialization of HBM7575/SKB575. Harbour BioMed supports this initiative through investment and shared development opportunities, collectively contributing to the advancement of this promising treatment.

Conclusion

The approval of HBM7575/SKB575 offers a beacon of hope for individuals whose lives are affected by atopic dermatitis. With its innovative approach and long-lasting effects, there is potential for a new era in therapeutic options that not only alleviate symptoms but also improve overall quality of life. Both companies look forward to the next steps in clinical development, with the aim of bringing this necessary treatment to market as soon as possible.

Looking Ahead

As Harbour BioMed and Kelun-Biotech continue their journey towards making HBM7575/SKB575 available to patients, the biopharmaceutical community watches closely. The transformation of clinical trials into real-world treatments can dramatically change the landscape for those with chronic skin conditions, and this development is one that deserves attention.